Skip to main content

IRTC

Stock
Health Care
Medical Devices

Performance overview

IRTC Price
Price Chart

Forward-looking statistics

Beta
1.30
Risk
54.69%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

Company info

SectorHealth Care
IndustryMedical Devices
Employees2K
Market cap$3.0B

Fundamentals

Enterprise value$5.1B
Revenue$618.6M
Revenue per employee
Profit margin-15.90%
Debt to equity848.67

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.13
Dividend per share
Revenue per share$19.74
Avg trading volume (30 day)$62M
Avg trading volume (10 day)$55M
Put-call ratio

Macro factor sensitivity

Growth-4.0
Credit+7.6
Liquidity+2.9
Inflation-6.3
Commodities-1.5
Interest Rates-4.7

Valuation

Dividend yield0.00%
PEG Ratio-77.43
Price to sales7.35
P/E Ratio-77.43
Enterprise Value to Revenue8.29
Price to book52.48

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

Zacks Investment Research (June 19, 2025)
Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts

iRhythm Technologies Inc IRTC on Thursday reported first quarter 2025 revenue of $158.7 million, up 20.3% year over year, beating the consensus of $153.38 million.

Benzinga (May 2, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free